JP2010270124A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010270124A5 JP2010270124A5 JP2010151115A JP2010151115A JP2010270124A5 JP 2010270124 A5 JP2010270124 A5 JP 2010270124A5 JP 2010151115 A JP2010151115 A JP 2010151115A JP 2010151115 A JP2010151115 A JP 2010151115A JP 2010270124 A5 JP2010270124 A5 JP 2010270124A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- dmxaa
- dimethylxanthenone
- acetic acid
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 9
- XGOYIMQSIKSOBS-UHFFFAOYSA-N vadimezan Chemical compound C1=CC=C2C(=O)C3=CC=C(C)C(C)=C3OC2=C1CC(O)=O XGOYIMQSIKSOBS-UHFFFAOYSA-N 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 4
- 229960004316 cisplatin Drugs 0.000 claims 4
- 230000002708 enhancing effect Effects 0.000 claims 4
- 230000001747 exhibiting effect Effects 0.000 claims 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 3
- 229960004397 cyclophosphamide Drugs 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229950008737 vadimezan Drugs 0.000 claims 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0121285.1A GB0121285D0 (en) | 2001-09-03 | 2001-09-03 | Anti-cancer combinations |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003524567A Division JP2005509599A (ja) | 2001-09-03 | 2002-09-03 | 抗癌組み合わせ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010270124A JP2010270124A (ja) | 2010-12-02 |
| JP2010270124A5 true JP2010270124A5 (enExample) | 2011-01-20 |
Family
ID=9921418
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003524567A Ceased JP2005509599A (ja) | 2001-09-03 | 2002-09-03 | 抗癌組み合わせ |
| JP2009133903A Pending JP2009263371A (ja) | 2001-09-03 | 2009-06-03 | 抗癌組み合わせ |
| JP2010151115A Pending JP2010270124A (ja) | 2001-09-03 | 2010-07-01 | 抗癌組み合わせ |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003524567A Ceased JP2005509599A (ja) | 2001-09-03 | 2002-09-03 | 抗癌組み合わせ |
| JP2009133903A Pending JP2009263371A (ja) | 2001-09-03 | 2009-06-03 | 抗癌組み合わせ |
Country Status (23)
| Country | Link |
|---|---|
| US (6) | US7863322B2 (enExample) |
| EP (3) | EP1423105B9 (enExample) |
| JP (3) | JP2005509599A (enExample) |
| CN (5) | CN100536840C (enExample) |
| AT (1) | ATE415963T1 (enExample) |
| AU (1) | AU2002324143B2 (enExample) |
| BR (1) | BR0212258A (enExample) |
| CA (1) | CA2458459A1 (enExample) |
| CY (1) | CY1110426T1 (enExample) |
| DE (1) | DE60230159D1 (enExample) |
| DK (1) | DK1423105T3 (enExample) |
| EA (3) | EA200801611A1 (enExample) |
| ES (1) | ES2321283T3 (enExample) |
| GB (1) | GB0121285D0 (enExample) |
| IL (1) | IL160178A0 (enExample) |
| IS (1) | IS7144A (enExample) |
| MX (1) | MXPA04002004A (enExample) |
| NO (1) | NO20040591L (enExample) |
| NZ (5) | NZ531045A (enExample) |
| PT (1) | PT1423105E (enExample) |
| SI (1) | SI1423105T1 (enExample) |
| WO (1) | WO2003020259A2 (enExample) |
| ZA (1) | ZA200401078B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY164077A (en) | 1999-05-13 | 2017-11-30 | Pharma Mar Sa | Compositions and uses of et743 for treating cancer |
| ATE324888T1 (de) * | 1999-06-14 | 2006-06-15 | Cancer Rec Tech Ltd | Krebstherapie |
| MXPA02011319A (es) | 2000-05-15 | 2003-06-06 | Pharma Mar Sa | Analogos antitumorales de ecteinascidina 743. |
| JP2004505047A (ja) | 2000-07-28 | 2004-02-19 | キャンサー・リサーチ・テクノロジー・リミテッド | 複合治療による癌治療 |
| GB0121285D0 (en) | 2001-09-03 | 2001-10-24 | Cancer Res Ventures Ltd | Anti-cancer combinations |
| GB0202544D0 (en) | 2002-02-04 | 2002-03-20 | Pharma Mar Sa | The synthesis of naturally occuring ecteinascidins and related compounds |
| GB2386836B (en) * | 2002-03-22 | 2006-07-26 | Cancer Res Ventures Ltd | Anti-cancer combinations |
| GB2394658A (en) | 2002-11-01 | 2004-05-05 | Cancer Rec Tech Ltd | Oral anti-cancer composition |
| GB0321999D0 (en) * | 2003-09-19 | 2003-10-22 | Cancer Rec Tech Ltd | Anti-cancer combinations |
| SI1689404T1 (sl) | 2003-11-13 | 2009-02-28 | Pharma Mar Sau | Kombinacija et-743 s 5-fluorouracil pro zdravili za zdravljenje raka |
| RS50510B (sr) | 2004-10-29 | 2010-03-02 | Pharma Mar S.A., Sociedad Unipersonal | Formulacije koje sadrže ekteinascidin i disaharid |
| GB0517387D0 (en) * | 2005-08-26 | 2005-10-05 | Antisoma Res Ltd | Combinations for the treatment of cancer |
| WO2007023302A1 (en) * | 2005-08-26 | 2007-03-01 | Antisoma Plc | Combinations comprising dmxaa for the treatment of cancer |
| GB0522082D0 (en) | 2005-10-31 | 2005-12-07 | Pharma Mar Sa | Formulations |
| GB0625283D0 (en) * | 2006-12-19 | 2007-01-24 | Cyclacel Ltd | Combination |
| CN101896177A (zh) * | 2007-12-13 | 2010-11-24 | 诺瓦提斯公司 | 用于治疗癌症的治疗剂的组合 |
| CN101279967B (zh) * | 2008-05-29 | 2010-11-10 | 武汉远大制药集团有限公司 | 一种治疗癌症的三甲基呫吨酮-4-乙酸药物组合物及其用途 |
| CN102203132A (zh) * | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
| US20100068302A1 (en) * | 2008-09-17 | 2010-03-18 | Traslational Cancer Drugs Pharma, S.L. | Methods and compositions for the treatment of cancer |
| WO2011019782A1 (en) * | 2009-08-11 | 2011-02-17 | Novartis Ag | Combinations of vascular disrupting agents with inhibitor of apoptosis proteins antagonists |
| DK2582847T3 (en) | 2010-06-18 | 2016-12-19 | Myriad Genetics Inc | METHODS AND MATERIALS TO ASSESS loss of heterozygosity |
| ES2588979T3 (es) | 2010-08-24 | 2016-11-08 | Dana-Farber Cancer Institute, Inc. | Procedimientos para la predicción de una respuesta contra el cáncer |
| CN102786509B (zh) * | 2011-05-16 | 2016-06-01 | 杭州民生药业有限公司 | 2-(5,6-二甲基呫吨酮-4-基)-乙酸的衍生物及其制备方法和用途 |
| CA2839210A1 (en) | 2011-06-17 | 2012-12-20 | Myriad Genetics, Inc. | Methods and materials for assessing allelic imbalance |
| AU2012358244A1 (en) | 2011-12-21 | 2014-06-12 | Myriad Genetics, Inc. | Methods and materials for assessing loss of heterozygosity |
| EP2617421A1 (en) * | 2012-01-20 | 2013-07-24 | Isofol Medical AB | Tetrahydrofolates in combination with EGFR-inhibitors in the use of treating cancer |
| CA3080441A1 (en) | 2012-02-23 | 2013-09-06 | The Children's Hospital Corporation | Methods for predicting anti-cancer response |
| CA2867434C (en) | 2012-06-07 | 2021-10-12 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| WO2014160080A1 (en) | 2013-03-14 | 2014-10-02 | Children's Medical Center Corporation | Cancer diagnosis, treatment selection and treatment |
| ES2777228T3 (es) | 2013-04-05 | 2020-08-04 | Myriad Genetics Inc | Métodos para evaluar la deficiencia de recombinación homóloga y predecir la respuesta al tratamiento del cáncer |
| WO2014169067A1 (en) * | 2013-04-09 | 2014-10-16 | Merrimack Pharmaceuticals, Inc. | Compositions for improving outcomes of liposomal chemotherapy |
| JP2016538344A (ja) * | 2013-11-19 | 2016-12-08 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | 癌処置としてのｓｔｉｎｇアゴニストの使用 |
| EP4023765A1 (en) | 2013-12-09 | 2022-07-06 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| CA2958801A1 (en) | 2014-08-15 | 2016-02-18 | Myriad Genetics, Inc. | Methods and materials for assessing homologous recombination deficiency |
| EP4141127B1 (en) | 2021-08-30 | 2024-10-09 | Zentrum Familiärer Brust- und Eierstockkrebs Universitätsklinik Köln | Method for assessing homologous recombination deficiency in ovarian cancer cells |
| CN115282140B (zh) * | 2022-02-07 | 2024-03-08 | 南京市儿童医院 | Aki治疗剂及dmxaa在制备该治疗剂中的应用 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2015265A1 (de) | 1969-03-29 | 1970-10-08 | Yoshitomi Pharmaceutical Industries Ltd., Osaka (Japan) | Arylalkansäuren und Verfahren zu deren Herstellung |
| US3655470A (en) * | 1969-03-29 | 1972-04-11 | Toa Gosei Chem Ind | Process for the production of a foamed thermoplastic resin sheet |
| US4565806A (en) * | 1981-08-18 | 1986-01-21 | Setaelae Kai M E | Composition and method for rational treatment of cancer |
| FR2516922A1 (fr) * | 1981-11-25 | 1983-05-27 | Lipha | Acides (oxo-4-4h-(1)-benzopyran-8-yl) alcanoiques, sels et derives, preparation et medicament les contenant |
| ATE92499T1 (de) * | 1984-12-04 | 1993-08-15 | Lilly Co Eli | Tumorbehandlung bei saeugetieren. |
| US4704355A (en) * | 1985-03-27 | 1987-11-03 | New Horizons Diagnostics Corporation | Assay utilizing ATP encapsulated within liposome particles |
| US5281620A (en) * | 1986-12-23 | 1994-01-25 | Cancer Research Campaign Technology Limited | Compounds having antitumor and antibacterial properties |
| ES2061518T3 (es) | 1986-12-23 | 1994-12-16 | Warner Lambert Co | Compuestos que tienen propiedades antitumorales y antibacterianas. |
| JPH01193227A (ja) | 1988-01-29 | 1989-08-03 | Res Dev Corp Of Japan | 癌免疫療法補助剤 |
| US5126129A (en) * | 1988-05-23 | 1992-06-30 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services | Cancer therapy using interleukin-2 and flavone compounds |
| US5075287A (en) | 1989-03-03 | 1991-12-24 | Nisshin Oil Mills, Inc. | Muramyl peptide derivatives and immunoregulating compositions containing them |
| CA2025907A1 (en) | 1989-09-21 | 1991-03-22 | Franklin D. Collins | Method of transporting compositions across the blood brain barrier |
| US5250296A (en) | 1990-11-29 | 1993-10-05 | Takeda Chemical Industries, Ltd. | Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine |
| EP0551200A1 (en) | 1992-01-07 | 1993-07-14 | National University Of Singapore | Protein phosphatase inhibitors for use in therapy |
| CA2086874E (en) | 1992-08-03 | 2000-01-04 | Renzo Mauro Canetta | Methods for administration of taxol |
| GB9308166D0 (en) * | 1993-04-20 | 1993-06-02 | Cancer Res Campaign Tech | Cancer therapy |
| GB9320484D0 (en) | 1993-10-05 | 1993-11-24 | Wellcome Found | Pharmaceutical combinations |
| DE4417742A1 (de) * | 1994-05-20 | 1995-11-23 | Bayer Ag | Nicht-systemische Bekämpfung von Parasiten |
| US5620875A (en) * | 1995-02-17 | 1997-04-15 | University Of Portland | Transfer of taxol from yew tree cuttings into a culture medium over time |
| WO1996032418A1 (en) | 1995-04-13 | 1996-10-17 | Laboratoires Om S.A. | Anti-cd14 antibodies for use in the induction of il-10 secretion |
| EP0743064A1 (en) | 1995-05-17 | 1996-11-20 | Eli Lilly And Company | Leukotriene antagonists for use in the treatment or prevention of alzheimer's disease |
| JPH0940690A (ja) | 1995-05-23 | 1997-02-10 | Yutaka Sashita | ステロイド配糖体及びこれを有効成分とする医薬 |
| WO1997004761A1 (en) | 1995-07-28 | 1997-02-13 | Trustees Of Boston University | Methods and compositions for treating cell proliferative disorders |
| US5977077A (en) | 1995-08-28 | 1999-11-02 | Interlab Corporation | Xanthone analogs for the treatment of infectious diseases |
| US5863904A (en) * | 1995-09-26 | 1999-01-26 | The University Of Michigan | Methods for treating cancers and restenosis with P21 |
| WO2000015176A2 (en) | 1998-09-10 | 2000-03-23 | Magainin Pharmaceuticals, Inc. | Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities |
| UA47505C2 (uk) | 1996-12-13 | 2002-07-15 | Елі Ліллі Енд Компані | Спосіб лікування плоскоклітинного раку ротової порожнини за допомогою антагоністів лейкотриєну |
| JP2001509143A (ja) | 1996-12-13 | 2001-07-10 | イーライ・リリー・アンド・カンパニー | 大脳病巣性卒中のためのロイコトリエンアンタゴニスト |
| AU5792398A (en) | 1996-12-13 | 1998-07-03 | Eli Lilly And Company | Leukotriene antagonists for treatment or inhibition of gout |
| DE69815310T2 (de) | 1997-03-11 | 2004-04-22 | Les Laboratoires Aeterna Inc. | Zubereitungen zur tumorbehandlung enthaltend hai-knorpelextrakte und antineoplastische mittel |
| HUP9904672A2 (hu) | 1997-03-21 | 2000-05-28 | Eli Lilly And Co. | Szájüregi laphámrák ellen alkalmazható leukotrién antagonisták |
| AU6450498A (en) | 1997-03-21 | 1998-10-20 | Eli Lilly And Company | Leukotriene antagonists useful for treating gout |
| AU6570798A (en) | 1997-03-21 | 1998-10-20 | Eli Lilly And Company | Leukotriene antagonists useful for treating gingivitis |
| US5998454A (en) | 1997-03-21 | 1999-12-07 | Eli Lilly And Company | Leukotriene antagonists useful for treating iritis |
| WO1998042345A1 (en) | 1997-03-21 | 1998-10-01 | Eli Lilly And Company | Leukotriene antagonists useful for treating cerebral focal stroke |
| AU6572298A (en) | 1997-03-21 | 1998-10-20 | Eli Lilly And Company | Leukotriene antagonists useful for treating ischemia reperfusion injury |
| AU6764798A (en) | 1997-03-21 | 1998-10-20 | Eli Lilly And Company | Leukotriene antagonists useful for treating cystic fibrosis |
| US5914340A (en) | 1997-03-21 | 1999-06-22 | Eli Lilly And Company | Leukotriene antagonists useful for treating dermatoses |
| DE19721211A1 (de) | 1997-05-21 | 1998-11-26 | Lindner Sen Wolfgang Dr Med | Kombination von antientzündlichen Wirkstoffen mit immunstimulierenden Agentien und zytotoxischen Agentien zur Behandlung von Tumoren |
| IL141627A0 (en) | 1998-08-24 | 2002-03-10 | Maxim Pharm Inc | Activation and protection of t-cells (cd4+and cd8+) using an h2 receptor agonist and other t-cell activating agents |
| AUPP609198A0 (en) | 1998-09-22 | 1998-10-15 | Curtin University Of Technology | Use of non-peptidyl compounds for the treatment of insulin related ailments |
| US6174873B1 (en) * | 1998-11-04 | 2001-01-16 | Supergen, Inc. | Oral administration of adenosine analogs |
| GB9903404D0 (en) | 1999-02-16 | 1999-04-07 | Angiogene Pharm Ltd | Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis |
| ATE289586T1 (de) * | 1999-03-01 | 2005-03-15 | Pfizer Prod Inc | Oxamsäuren mit einer cyanogruppe als liganden für den thyroidrezeptor |
| ATE324888T1 (de) | 1999-06-14 | 2006-06-15 | Cancer Rec Tech Ltd | Krebstherapie |
| US6806257B1 (en) * | 1999-10-20 | 2004-10-19 | Board Of Trustees Of Southern Illinois University | Flavones as inducible nitric oxide synthase inhibitors, cyclooxygenase-2 inhibitors and potassium channel activators |
| AU778829B2 (en) | 1999-11-11 | 2004-12-23 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
| EP1231939A2 (en) | 1999-11-11 | 2002-08-21 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
| WO2001034197A2 (en) | 1999-11-11 | 2001-05-17 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
| WO2001034198A2 (en) | 1999-11-11 | 2001-05-17 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
| EP1259237A4 (en) * | 2000-02-17 | 2004-07-28 | Merck & Co Inc | TREATMENT AND PROPHYLAXIS OF PROSTATE CANCER WITH COX-2 SELECTIVE INHIBITORS |
| JP2001247459A (ja) * | 2000-03-03 | 2001-09-11 | Oakland Uniservices Ltd | 癌の組み合わせ療法 |
| JP2004505047A (ja) * | 2000-07-28 | 2004-02-19 | キャンサー・リサーチ・テクノロジー・リミテッド | 複合治療による癌治療 |
| GB0121285D0 (en) * | 2001-09-03 | 2001-10-24 | Cancer Res Ventures Ltd | Anti-cancer combinations |
| GB2386836B (en) * | 2002-03-22 | 2006-07-26 | Cancer Res Ventures Ltd | Anti-cancer combinations |
| GB2394658A (en) | 2002-11-01 | 2004-05-05 | Cancer Rec Tech Ltd | Oral anti-cancer composition |
| GB0321999D0 (en) | 2003-09-19 | 2003-10-22 | Cancer Rec Tech Ltd | Anti-cancer combinations |
| GT200500186A (es) * | 2004-07-07 | 2006-03-02 | Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits | |
| WO2007023302A1 (en) | 2005-08-26 | 2007-03-01 | Antisoma Plc | Combinations comprising dmxaa for the treatment of cancer |
| GB0517387D0 (en) | 2005-08-26 | 2005-10-05 | Antisoma Res Ltd | Combinations for the treatment of cancer |
| MX2010003594A (es) | 2007-10-23 | 2010-09-22 | Antisoma Res Ltd | Formas cristalinas de sal sodica de dmxaa. |
-
2001
- 2001-09-03 GB GBGB0121285.1A patent/GB0121285D0/en not_active Ceased
-
2002
- 2002-09-03 ES ES02758562T patent/ES2321283T3/es not_active Expired - Lifetime
- 2002-09-03 NZ NZ531045A patent/NZ531045A/en not_active IP Right Cessation
- 2002-09-03 EA EA200801611A patent/EA200801611A1/ru unknown
- 2002-09-03 NZ NZ567456A patent/NZ567456A/en not_active IP Right Cessation
- 2002-09-03 EA EA200601118A patent/EA010857B1/ru not_active IP Right Cessation
- 2002-09-03 AT AT02758562T patent/ATE415963T1/de active
- 2002-09-03 PT PT02758562T patent/PT1423105E/pt unknown
- 2002-09-03 AU AU2002324143A patent/AU2002324143B2/en not_active Ceased
- 2002-09-03 CN CNB028172574A patent/CN100536840C/zh not_active Expired - Fee Related
- 2002-09-03 EP EP02758562A patent/EP1423105B9/en not_active Expired - Lifetime
- 2002-09-03 NZ NZ546573A patent/NZ546573A/en not_active IP Right Cessation
- 2002-09-03 CN CNA2009101604084A patent/CN101607087A/zh active Pending
- 2002-09-03 CA CA002458459A patent/CA2458459A1/en not_active Abandoned
- 2002-09-03 BR BR0212258-8A patent/BR0212258A/pt not_active IP Right Cessation
- 2002-09-03 DE DE60230159T patent/DE60230159D1/de not_active Expired - Lifetime
- 2002-09-03 JP JP2003524567A patent/JP2005509599A/ja not_active Ceased
- 2002-09-03 MX MXPA04002004A patent/MXPA04002004A/es active IP Right Grant
- 2002-09-03 EP EP06077049A patent/EP1759694A3/en not_active Withdrawn
- 2002-09-03 IL IL16017802A patent/IL160178A0/xx unknown
- 2002-09-03 CN CNA2009101604099A patent/CN101596186A/zh active Pending
- 2002-09-03 EP EP10001750A patent/EP2236134A1/en not_active Withdrawn
- 2002-09-03 CN CNA2006101513931A patent/CN1994287A/zh active Pending
- 2002-09-03 NZ NZ576925A patent/NZ576925A/en not_active IP Right Cessation
- 2002-09-03 WO PCT/GB2002/004025 patent/WO2003020259A2/en not_active Ceased
- 2002-09-03 DK DK02758562T patent/DK1423105T3/da active
- 2002-09-03 NZ NZ554093A patent/NZ554093A/en not_active IP Right Cessation
- 2002-09-03 EA EA200400370A patent/EA008056B1/ru not_active IP Right Cessation
- 2002-09-03 CN CNA2009101604101A patent/CN101596187A/zh active Pending
- 2002-09-03 SI SI200230798T patent/SI1423105T1/sl unknown
-
2004
- 2004-02-06 IS IS7144A patent/IS7144A/is unknown
- 2004-02-10 NO NO20040591A patent/NO20040591L/no unknown
- 2004-02-10 ZA ZA200401078A patent/ZA200401078B/en unknown
- 2004-03-02 US US10/790,943 patent/US7863322B2/en not_active Expired - Fee Related
-
2006
- 2006-11-03 US US11/592,678 patent/US20070060637A1/en not_active Abandoned
-
2007
- 2007-07-30 US US11/830,668 patent/US7863320B2/en not_active Expired - Fee Related
- 2007-07-30 US US11/830,677 patent/US7863321B2/en not_active Expired - Fee Related
- 2007-07-30 US US11/830,650 patent/US7868039B2/en not_active Expired - Fee Related
- 2007-07-30 US US11/830,659 patent/US7868040B2/en not_active Expired - Fee Related
-
2008
- 2008-12-31 CY CY20081101516T patent/CY1110426T1/el unknown
-
2009
- 2009-06-03 JP JP2009133903A patent/JP2009263371A/ja active Pending
-
2010
- 2010-07-01 JP JP2010151115A patent/JP2010270124A/ja active Pending